Conventional Cell Line Models for Virus Studies {#Sec1}
===============================================

Emerging and re-emerging viral infections are becoming severe global public health problems in the current century. In February 2003, an outbreak of severe acute respiratory syndrome (SARS), caused by SARS coronavirus (SARS-CoV), was reported in Guangdong, China (Ksiazek *et al*. [@CR44]). The SARS-CoV infected 8096 cases and 774 deaths worldwide. In March 2009 a novel influenza virus (H1N1pdm) emerged in the United States and Mexico. H1N1pdm obtained the capacity to transmit in humans and quickly spread to more than 214 countries (Hendrickson and Matthay [@CR31]). Thereafter the H1N1 infection became a seasonal virus circulating over the world (Dawood *et al*. [@CR20]). Middle East respiratory syndrome (MERS) coronavirus was isolated from patients who developed acute pneumonia and renal failure in 2012 from Saudi Arabia (Zaki *et al*. [@CR103]). One big secondary outbreak with 186 confirmed cases was in South Korea in 2015. Up to January 2020, more than 2500 confirmed cases were reported with a case fatality of 34.4% (WHO [@CR112]). In December 2019, a novel coronavirus, SARS-CoV-2 caused an outbreak of acute pneumonia in Wuhan City of China (Zhou P *et al*. [@CR109]).The current animal models for study of SARS-CoVs include African green monkeys, macaques, ferret, and mice (Kong *et al*. [@CR41]; Smits *et al*. [@CR79]). These *in vivo* models are useful for studying many important questions, for example, local or systemic pathogenic changes, immune response, and drug metabolism and *in vivo* efficacy. However, these animal models have limitations due to species difference. The viral tropism correlates to expression of viral receptor(s) on the surface of host cells and intracellular restriction as well. Cancer cell lines have been used widely for biological or functional cell systems in many other fields (Agarwal and Rimm [@CR1]; Barretina *et al*. [@CR5]; Palechor-Ceron *et al*. [@CR65]). These cells are defective for many functions of normal human cells because of significant genetic and epigenetic changes compared to the normal tissues. However, primary cell yields and viability from any original tissue specimens are often relatively low or highly variable. These normal cells cease at a few passages because of very limited proliferative capacity *in vitro*. It has been extremely difficult for decades to generate and maintain normal cell lines. Several exogenous immortalization approaches have been used to establish primary cell lines from variety of tissue types. For example, viral oncogenes such as SV40 large T antigen or the human papillomavirus (HPV) E6/E7 proteins can bypass the cell senescence block through interfering with p53 and Rb regulatory pathways (Liu *et al*. [@CR48]; Liu *et al*. [@CR49]; Liu *et al*. [@CR50]; Cid Arregui *et al*. [@CR17]; Klingelhutz and Roman [@CR40]; Ghittoni *et al*. [@CR29]). Expression of exogenous cellular genes (hTERT, c-Myc, cdk4, etc.) or inactivation of cellular tumor repressors (p53, pRB, etc.) can be widely used to immortalize primary human normal cells, which leads to disrupted cell differentiation or loss of tissue type-specific functions (Liu *et al*. [@CR52]).

We observed that two classes of functions are required for cell immortalization by HPV E6 and E7: telomerase activation and actin cytoskeleton alterations (Fu *et al*. [@CR27]; Charette and McCance [@CR15]; Liu *et al*. [@CR49]; Liu *et al*. [@CR50]; Yue *et al*. [@CR102]; Klingelhutz and Roman [@CR40]). We also noted that feeder cells and altered molecular pathways activate telomerase (Fu *et al*. [@CR27]; Liu *et al*. [@CR50]; Liu *et al*. [@CR51]; Klingelhutz and Roman [@CR40]; Liu *et al*. [@CR52]), and a Rho-Kinase inhibitor, Y-27632, disrupts the actin cytoskeleton and inactivate Rho (Chapman *et al*. [@CR14]; Liu *et al*. [@CR52]). Unexpectedly, combination of feeder layers and Y-27632 allows to rapidly establish both normal and tumor cell cultures from non-keratinocyte tissues (Liu *et al*. [@CR52]; Suprynowicz *et al*. [@CR81]; Palechor-Ceron *et al*. [@CR64]; Liu *et al*. [@CR53]). We also demonstrated that the effect of the combined co-culture condition is rapid (2 days), and the whole cell populations are shifted or reprogrammed rather than a clone selection as conventional cancer cell lines (Liu *et al*. [@CR52]; Suprynowicz *et al*. [@CR81]). These cell cultures stop proliferating if one of the conditions (Y-27632 or feeder layer) is not met. We termed this culture method and resulting cells as "conditional reprogramming (CR)" and "conditionally reprogrammed cells (CRC)", respectively (Liu *et al*. [@CR52]; Suprynowicz *et al*. [@CR81]; Palechor-Ceron *et al*. [@CR64]; Liu *et al*. [@CR53]; Palechor-Ceron *et al*. [@CR65]). Indeed, organoids (Weeber *et al*. [@CR89]; Puca *et al*. [@CR68]; Sachs *et al*. [@CR71]; Mullenders *et al*. [@CR62]; Xinaris [@CR95]) and CR technologies have been widely used in cancer biology and regeneration fields. They both have been recognized as the key new technologies by NCI (National Cancer Institute) precision oncology (<https://ocg.cancer.gov/programs/hcmi/research>) (Friedman *et al*. [@CR26]; Senft *et al*. [@CR73]), which are used for HCMI (human cancer model initiatives) program launched during 2019 annual AACR) ([https://www.atcc.org/en/Products/Cells_and_Microorganisms/HCMI.aspx?utm_id&equals;t18020438l1](https://www.atcc.org/en/Products/Cells_and_Microorganisms/HCMI.aspx%3futm_id%26equals%3bt18020438l1)). Table [1](#Tab1){ref-type="table"} lists properties of these cell models. In this review, we will highlight roles of CRC and coupled air-liquid interface (ALI) system in studies of emerging viruses.Table 1Comparison of *ex vivo* cell models.Conventional cell linesOrganoidsCRCSample sizeSurgicalSmall to bigTiny to bigTiming1--5 months1--5 weeks1--10 daysSuccess rate of initiation (%)(0--10)++ (5--80)+++ (50--100)Rapid expansion++++++++Karyotypic stability+++++3D growth--++--Genetic manipulation+++++++Low throughput drug screens++++++++High throughput drug screens++++++++Heterogeneity−++++Cell biology+++++++Cost++++"--" "+" "++" and "+++" indicate "unsuitable or not applicable", "possible", "suitable", and "best" for the aspects or applications except for "cost". "+" and "++" represent "low" and "high" for in "cost" line, respectively.

CR Methodology {#Sec2}
==============

Primary airway epithelial cells can be obtained from airway tract using non-invasive or minimally invasive techniques, nasal brushing, nasorophynx swaps, induced sputum sample collection, bronchiolar lavage, endobronchial brushing or biopsy. After CR technology was established in 2012, the CR protocol has been proven to easily establish patient-derived normal and cancer cell cultures without genetic manipulation (Liu *et al*. [@CR52]; Palechor-Ceron *et al*. [@CR64]; Liu *et al*. [@CR53]). Originally, the CR used irradiated mouse fibroblast cells (swiss mouse 3T3, J2 clone) and the Rho-associated kinase inhibitor (Y-27632) to propagate epithelial cells (Liu *et al*. [@CR52]; Palechor-Ceron *et al*. [@CR64]; Liu *et al*. [@CR53]). A few improvements have been used to simplify protocols using J2 conditioned medium (Liu *et al*. [@CR52]; Palechor-Ceron *et al*. [@CR64]; Liu *et al*. [@CR53]), hypoxia condition (1%--2% O~2~) (Peters-Hall *et al*. [@CR67]), and combination with dual TGF-beta/SMAD inhibition (Mou *et al*. [@CR61]; Zhang C *et al*. [@CR104]). CR technology is simple and cheap since there is no need for expensive reagents as matrigel for organoids, robust since 1 × 10^6^ cells can be generated from a needle biopsy within 7 days, and rapid since the whole populations of cells can be reprogrammed within 2 days instead of clonal selection. Figure [1](#Fig1){ref-type="fig"} shows a diagram of normal cell cultures in CR conditions and 3D (ALI and non-iPS organoids) conditions for *ex vivo* models of airway epithelial cells.Fig. 1Workflow for *ex vivo* models of human normal airway epithelial cells.

CRCs Maintain Differentiation Potential and Lineage Functions of Normal Airway Epithelial Cells {#Sec3}
===============================================================================================

CR allows the rapid generation of multi-lineage cell cultures (conditionally reprogrammed cells, CRC) from many different normal epithelial tissues, as well as tumors derived from these sites (Liu *et al*. [@CR52]; Suprynowicz *et al*. [@CR81]; Palechor-Ceron *et al*. [@CR64]; Liu *et al*. [@CR53]; Palechor-Ceron *et al*. [@CR65]). Normal cell lines retain their normal karyotype and growth properties, and tumor cells retain their tumorigenic potential (Liu *et al*. [@CR52]; Suprynowicz *et al*. [@CR81]; Palechor-Ceron *et al*. [@CR64]; Borodovsky *et al*. [@CR8]; Liu *et al*. [@CR53]; Yuan *et al*. [@CR101]; Alkhilaiwi *et al*. [@CR3]; Correa *et al*. [@CR18]; Palechor-Ceron *et al*. [@CR65]). Interestingly, generation of CRC from normal tissue is reversible, and manipulating CR conditions allows the cells to differentiate normally (Suprynowicz *et al*. [@CR81]; Liu *et al*. [@CR53]). For example, when CRC from skin epithelium or tracheal epithelium are placed in an ALI culture system, the skin cells form a well-differentiated stratified squamous epithelium, whereas the tracheal cells form a ciliated airway epithelium.

CRCs at ALI {#Sec4}
===========

ALI (Air--Liquid interface) culture (Fig. [2](#Fig2){ref-type="fig"}) of CR airway cells is uniquely suited as a model for *in vitro* infection studies. This is due to the ability of ALI cultures to faithfully recapitulate key characteristics of the *in vivo* airway. For example, ALI cultures exhibit relevant proportions of airway cell types, appropriate cellular polarization and junctional properties, dynamic physiologic processes such as mucus secretion and coordinated ciliary beating, and physiological expression and subcellular localization of characteristic proteins bearing species-specific sequences.Fig. 2Air-liquid interface (ALI) differentiation cultures of normal airway conditionally reprogrammed cells (CRCs). **A** Histological sections of ALI cultures of CRCs. Sections were stained with H&E or a combination of alcian blue and periodic acid-Schiff reaction (AB-PAS). Note the presence of ciliated cells (arrowheads) and mucus-producing cells (arrows). **B** Confocal microscopy of tracheal-bronchial CRCs that were differentiated in ALI culture, fixed and fluorescently labeled with phalloidin (F-actin), Hoechst dye 33342 (DNA), or antibodies demonstrating the presence of cilia (alpha-tubulin) and mucins 5AC and 5B (MUC5AC/MUC5B). An *X*--*Z* cross-section, extended focus *X*--*Y* view, and corresponding three-dimensional (3D) view are shown. (adapted from PNAS (<https://www.pnas.org/page/authors/licenses>), (Suprynowicz *et al*. [@CR81]).

CRCs/ALI: An *Ex Vivo* Models for Virus Infections {#Sec5}
==================================================

To date, CR by itself or in combination with ALI cultures have been used in studies of host defense and viral infections, drug screening and toxicity testing, wound healing/repair, gene therapies as *ex vivo* preclinical models for lung cancer, chronic obstructive pulmonary disease, cystic fibrosis, and asthma (Yuan *et al*. [@CR100]; Bove *et al*. [@CR10]; Crystal *et al*. [@CR19]; Saenz *et al*. [@CR72]; Chu *et al*. [@CR16]b; Feng *et al*. [@CR23]; Kotha *et al*. [@CR42]; Walters *et al*. [@CR85]; Alamri *et al*. [@CR2]; Beglyarova *et al*. [@CR6]; Butler *et al*. [@CR12]; Ellis *et al*. [@CR22]; Papapetrou [@CR66]; Reynolds *et al*. [@CR69]; Borodovsky *et al*. [@CR8]; Gentzsch *et al*. [@CR28]; Jensen *et al*. [@CR34]; Li *et al*. [@CR46]; Mahajan *et al*. [@CR55]; Martinovich *et al*. [@CR57]; Wolf *et al*. [@CR90]; Yu *et al*. [@CR99]; Yuan *et al*. [@CR101]; Alkhilaiwi *et al*. [@CR3]; Boström *et al*. [@CR9]; Brewington *et al*. [@CR11]; Correa *et al*. [@CR18]; Jin *et al*. [@CR37]; LaRanger *et al*. [@CR45]; Mimoto *et al*. [@CR58]; Moorefield *et al*. [@CR60]; Peters-Hall *et al*. [@CR67]; Shay *et al*. [@CR74]; Wang *et al*. [@CR87]; Zhang Z *et al*. [@CR105]; Alkhilaiwi *et al*. [@CR4]; Jiang *et al*. [@CR36]; Krawczyk *et al*. [@CR43]; Liu [@CR47]; Martini *et al*. [@CR56]; Mondal *et al*. [@CR59]; Nicolas *et al*. [@CR63]; Palechor-Ceron *et al*. [@CR65]; Su *et al*. [@CR80]; Chai *et al*. [@CR13]). Compared to organoids (close 3D cultures) shown in Fig. [1](#Fig1){ref-type="fig"} (right lower panel), ALI system is much easier for virology studies because of an open apical area for infections or viral inoculations (Fig. [3](#Fig3){ref-type="fig"}). Here we will focus our discussion on applications of this physiological system in respiratory virus infections. Figure [3](#Fig3){ref-type="fig"} shows many aspects of studies of emerging viruses.Fig. 3Potential applications of CR/ALI cultures in emerging viruses.

Roberts *et al*. collected samples from paired nasal and bronchial brushings and cultured and expanded nasal and bronchial epithelial cells using CR condition (irradiated 3T3 fibroblasts in presence of Y-27632) (Roberts *et al*. [@CR70]). Passaged cells were then put onto collagen coated transwells in 12 well plates for ALI culture. They found that viral infection in both cell types increased the expression of IP-10 (interferon gamma-induced protein 10), although the increase was only significant in the ALI culture, with combining rhinovirus infection and IL-13 treatment (Roberts *et al*. [@CR70]). Kotha *et al*. showed that the level of the apical adenovirus receptor (CAR^Ex8^) and physiologically relevant levels of IL-8 and neutrophils (components of the innate immune system) enhanced entry of adenovirus in polarized human airway epithelia (Kotha *et al*. [@CR42]). Jonsdottir *et al*. established CRC and ALI cultures from both upper and lower airway to study the host innate immune response to human coronavirus 229E (HCoV-229E) and human respiratory syncytial virus (RSV) after gene manipulations (Jonsdottir *et al*. [@CR38]). It is well known that autonomous parvovirus replication depends on the S phase of the host cells. Interestingly, Deng *et al*. ([@CR21]) reported for the first time parvovirus DNA replicated in non-dividing cells autonomously. They first established CR cells and ALI cultures (non-dividing airway epithelial cells) and inoculated ALI with human parvovirus HBoV1. Their results demonstrated that HBoV1 infection of ALI cultures induces a DNA damage response (DDR), thereby facilitating viral genome amplification. They also discovered that Y- family DNA repair polymerases, Pol η and Pol κ, are involved in HBoV1 genome amplification in ALI system. This is the first report to show that parvovirus DNA replicates in non-dividing cells autonomously. Zhu *et al*. studied HSV-2 infection in CR and ALI cultured normal vaginal epithelial cells (Zhu *et al*. [@CR110]). Fink *et al*. also established CR cells from routine vaginal repair surgeries or hysterectomies and studied antiviral drug (Arbidol) Inhibition of Zika virus (Fink *et al*. [@CR25]). Finally, Imai-Matsushima *et al*. generated long-term culture of distal airway epithelial cells and differentiated alveolar epithelial cells that are suited for influenza virus study (Imai-Matsushima *et al*. [@CR33]).

CRCs/ALI: Potential Applications in SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19) {#Sec6}
======================================================================================

On Jan. 30 and March 11, 2020, the International Health Regulations Emergency Committee World Health Organization (WHO) declared the COVID-19 or SARS-CoV-2 infection outbreak as a "public health emergency of international concern", and characterized COVID-19 as a pandemic, respectively (WHO [@CR92]). COVID-19 cases have ranged from very mild (including asymptomatic), mild, moderate, severe, and critical severe including illness resulting in death (Lu *et al*. [@CR54]; Singhal [@CR78]; Wang *et al*. [@CR88]; Wu and McGoogan [@CR94]; Yang S *et al*. [@CR96]; Yang X *et al*. [@CR97]; Ye *et al*. [@CR98]; Zhang *et al*. [@CR106]; Zhou C *et al*. [@CR107]; Zhou F *et al*. [@CR108]; Zou *et al*. [@CR111]). COVID-19 common symptoms include fever, cough and shortness of breath. Muscle pain, sputum production and sore throat are less common (Lu *et al*. [@CR54]; Singhal [@CR78]; Wang *et al*. [@CR88]; Wu and McGoogan [@CR94]; Yang S *et al*. [@CR96]; Yang X *et al*. [@CR97]; Ye *et al*. [@CR98]; Zhang *et al*. [@CR106]; Zhou C *et al*. [@CR107]; Zhou F *et al*. [@CR108]; Zou *et al*. [@CR111]). While the majority of cases result in mild symptoms, some progress to severe pneumonia and multi-organ failure including lung, heart, and kidney (Lu *et al*. [@CR54]; Singhal [@CR78]; Wang *et al*. [@CR88]; Wu and McGoogan [@CR94]; Yang S *et al*. [@CR96]; Yang X *et al*. [@CR97]; Ye *et al*. [@CR98]; Zhang *et al*. [@CR106]; Zhou C *et al*. [@CR107]; Zhou F *et al*. [@CR108]; Zou *et al*. [@CR111]). The rate of deaths per number of diagnosed cases is estimated to be 3.4% but varies by age and other health conditions (Lu *et al*. [@CR54]; Singhal [@CR78]; Wang *et al*. [@CR88]; Wu and McGoogan [@CR94]; Yang S *et al*. [@CR96]; Yang X *et al*. [@CR97]; Ye *et al*. [@CR98]; Zhang *et al*. [@CR106]; Zhou C *et al*. [@CR107]; Zhou F *et al*. [@CR108]; Zou *et al*. [@CR111]). The mechanisms how SARS-CoV-2 infects human airway epithelial cells and also causes severe multi-organ failure are largely unknown. Generally speaking, early stage of COVID-19 or cases with very mild (including asymptomatic), mild symptoms are usually due to rapid replication of viruses at local areas, innate response of the host cells and local immune-response (IgA). Severe cases with multi-organ injury are usually due to possible viral replications in the target organs and immunopathogenic injuries (including cytokine storm or antibody dependent enhancement). Recently, two reports demonstrated that large amounts of SARS-CoV-2 were detected in the upper airway and saliva (To *et al*. [@CR82]; Zou *et al*. [@CR111]).

SARS-CoV-2 and SARS-CoV share the same functional host-cell receptor ACE2 (Hoffmann *et al*. [@CR32]; Walls *et al*. [@CR84]; Wan *et al*. [@CR86]; Wrapp *et al*. [@CR93]; Zhou P *et al*. [@CR109]) and sequence analysis reveals that SARS-CoV-2 possesses crucial amino acid residues for ACE2 binding (Hoffmann *et al*. [@CR32]). ACE2 predominantly expresses in vascular endothelial cells, kidney and heart tissues, small intestine, and testes (Hamming *et al*. [@CR30]). The distribution of ACE2 in human tissues does not seem to correlate with diseases with COVID-19, while this may help explain why severe cases with COVID-19 have multi-organ failure including heart and kidney. It is important to understand body site-specific or tissue-specific viral replication, innate immune response, and infectivity. Two recent reports demonstrated that large amounts of SARS-CoV-2 were found in the upper airway and saliva as we described above (To *et al*. [@CR82]; Zou *et al*. [@CR111]), where ACE2 is not expressed or expresses at very low levels. Wolfel *et al*. performed a dynamic viral analysis of nine COVID-19 patients, they showed active virus replication in upper airway tissues. Virus shedding at pharynx was very high at the first week of symptoms, the peak was at 7.11 × 10^8^ RNA copies per throat swab at day 4. SARS-CoV-2 viruses were readily cultured from throat- and lung-derived samples, but not from stool samples with high viral RNA. Viral load was declined after 7 days of symptoms (Wolfel *et al*. [@CR91]). A ferret model of SASR-CoV-2 infection and transmission was established recently (Kim *et al*. [@CR39]), which can recapitulate some aspects of human COVID-19 disease. SARS-CoV-2-infected ferrets shed virus in nasal washes, saliva, urine, and feces up to 8 days after infection. Viral antigens were also detected in several tissues, as nasal cavity, trachea, lung, and intestine. This ferret model represents an animal model of SARS-CoV-2 infection and transmission, may facilitate to develop COVID-19 therapeutics and vaccine as well. However, distribution of ACE2 and viral replication in different organs or tissues, or possible other receptors or co-receptors in this model need to be further determined. Another study also demonstrated that SARS-CoV-2 may replicate well in ferrets and cats, but poorly in dogs, pigs, chickens, and ducks (Shi *et al*. [@CR77]). These inconsistences suggest possible alternative receptors or co-receptors on the surface of the target cells in different tissues. A study by Blanco-Melo *et al*. suggests that human alveolar adenocarcinoma cells (A549) are able to support viral replication of SARS-CoV-2, RSV and influenza A virus, despite undetectable levels of ACE2 and TMPRSS2, the putative receptor and protease for SARS-CoV-2 entry (Blanco-Melo *et al*. [@CR7]). To solve these problems, we will need comprehensive studies of tissue staining of viral antigens and cellular proteins from COVID-19 patients. Then, human related physiological models are urgently needed to investigate these questions and for functional validation. In agreement with these arguments, an early study on SARS-CoV indicates that host cell differentiation or polarized epithelium and expression of ACE2 are both important for the susceptibility of human airway epithelia to SARS-CoV viral infection (Jia *et al*. [@CR35]; Tseng *et al*. [@CR83]). Indeed, ALI cultures of human airway epithelial cells (HAEs) have also been used for functional drug screening of SARS-CoV and SARS-CoV-2 (Sheahan *et al*. [@CR75]; Sheahan *et al*. [@CR76]). Since CRCs are stable resources for normal functional airway cells, CRCs/ALI cultures will facilitate these studies and development of novel therapeutics as a functional and biological system.

Advantage and Limitations {#Sec7}
=========================

As we discussed above, CR is a rapid, robust and sufficient way to obtain large amount of normal airway cells from non-invasive and minimal human samples, and CRCs from respiratory tract maintain their lineage functions. ALI provides a unique environment to mimic "*in vivo*" physiological conditions. Thus, CRC/ALI will be appropriate for studies of viral entry to the nature host cells, innate immune response of the host cells, and tests of anti-viral and immune (innate) modulators (Fig. [3](#Fig3){ref-type="fig"}). This will be a unique biological or functional cell system for population or health disparity studies since there is no biological cell model available in the field. Since CRCs can be easily genetically manipulated with overexpression of exogenous genes, shRNAs, or CRISPR technologies (Chu *et al*. [@CR16]a; Fenini *et al*. [@CR24]), CRC/ALI should be a unique system for both phenotypical and mechanism studies for human viral diseases. Although CRCs alone can be used for rapid and high throughput screening, combination CRC and ALI will take much longer time and need further development for high throughput studies. Compare to the current permissive cancer cell lines or animal derived permissive cell lines, CRC/ALI for virus studies requires experienced performance, higher work load and cost. Thus, CRC/ALI will serve as a human-relevant, physiological system for emerging viruses in addition the current cell lines and animal models.

Conclusions {#Sec8}
===========

Because of limitations of current cell line and animal models, there is an urgent need of human physiological cell models for studies of emerging viruses. Here we summarized establishment of long term cultures for human normal airway epithelial cells from nose to lung using CR and coupled ALI technologies and their applications as an *ex vivo* model for emerging viruses. As a great addition to the current cell lines and animal models, CRC/ALI system will facilitate studies of viral entry including receptors and internalization, innate immune responses, viral replications, and drug discovery.
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